ArticleVaccines2025
RSV Vaccination Programme for Older Adults: A Scotland-Wide Study on RSVpreF Vaccine Safety.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A narrative review of considerations when assessing potential relationships between Guillain-Barré syndrome and vaccines.Human vaccines & immunotherapeutics · 2026Review
- AS01Drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesRespiratory Syncytial Virus (RSV) is a common respiratory tract infection that accounts for significant morbidity and mortality, particularly among older adults. From 1 August 2024, the bivalent RSVpreF vaccine (Abrysvo
methodsWe conducted observed versus expected (OE) and self-controlled case series (SCCS) analyses to retrospectively monitor the incidence of hospital admission for 39 conditions, including GBS. This was undertaken in post-RSV-vaccination periods from 1 August to 31 December 2024, among eligible adults aged 74 to 80 years in Scotland.
resultsObserved versus expected analyses identified an increased risk of hospitalisation with GBS in the 1-28-day post-vaccination period. From SCCS analyses, six conditions showed an increased risk in post-vaccination periods (acute coronary syndrome, acute myocardial infarction, acute renal failure, GBS, heart failure and stroke (haemorrhagic)). After temporal adjustment, only GBS remained significant. All 10 hospitalised GBS cases occurred in the 10 to 16 days post-vaccination. Excess risk of GBS was estimated to be 46.1 cases per one million doses.
conclusionsStudy results indicated a good safety profile of the RSV vaccine for older eligible adults aged 75 to 79 years, although a small increased risk of GBS was identified in both analyses. Excess risk levels of GBS from vaccination align with other studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.